<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130426</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT-iGlarLixi</org_study_id>
    <nct_id>NCT03130426</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi</brief_title>
  <acronym>REMIT-iGL</acronym>
  <official_title>Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether in patients with early type 2 diabetes, a
      short-term intensive metabolic intervention comprising iGlarLixi, metformin, and lifestyle
      approaches will be superior to standard diabetes therapy in achieving sustained diabetes
      remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized controlled trial in 160 patients with
      recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week
      course of treatment with iGlarLixi, metformin and lifestyle therapy, and (b) standard
      diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all
      participants with HbA1C&lt;7.3% at the 12 week visit, glucose-lowering medications will be
      discontinued and participants will be encouraged to continue with lifestyle modifications and
      regular glucose monitoring. Participants with HbA1C â‰¥ 7.3% at this visit or who experience
      hyperglycemia relapse after stopping drugs will receive standard glycemic management as
      informed by the current Canadian Diabetes Association clinical practice guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission</measure>
    <time_frame>36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free normoglycemia defined as HbA1C &lt; 6.0%</measure>
    <time_frame>24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free normoglycemia defined as HbA1C &lt; 5.7%</measure>
    <time_frame>24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes regression</measure>
    <time_frame>24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
    <description>Diabetes regression is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss from baseline</measure>
    <time_frame>12 weeks, 24 weeks, 36 weeks, 48 weeks and 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>12 weeks, 24 weeks, 36 weeks, 48 weeks and 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-point capillary glucose profile</measure>
    <time_frame>1 week, 6 weeks, 12 weeks, 24 weeks and 48 weeks</time_frame>
    <description>measured on 2 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iGlarLixi</intervention_name>
    <description>Dose is titrated to achieve fasting normoglycemia</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>glargine insulin / lixisenatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Dose is titrated to 2000 mg daily or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle therapy</intervention_name>
    <description>Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>diet and exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. men and women aged 30-80 years;

          2. type 2 diabetes mellitus within 5 years of diagnosis;

          3. stable diabetes drug regimen in the 10 weeks before randomization;

          4. HbA1c 6.5-9.5% on no glucose lowering drugs, or &lt;/= 8.5% on 1 glucose-lowering drug,
             or &lt;/= 8.0% on 2 glucose lowering drugs;

          5. body mass index &gt;/= 23 kg/m2;

          6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);

          7. ability and willingness to self-inject iglarlixi; and

          8. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy;

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;

          3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR&lt;45
             mL/min/1.73 m2 by MDRD formula;

          4. history of lactic acidosis or diabetic ketoacidosis;

          5. active liver disease or elevated alanine transferase (ALT) levels &gt;\= 2.5 times upper
             limit of normal at the time of enrolment;

          6. history or clinical suspicion of pancreatitis or medullary thyroid cancer, or a
             calcitonin level &gt;/= 20 pg/ml;

          7. cardiovascular disease (unless cleared for a moderate intensity exercise program by a
             specialist) including: i. acute coronary syndrome, hospitalization for unstable
             angina, myocardial infarction, or revascularization with coronary artery bypass
             grafting or percutaneous coronary intervention; ii. peripheral vascular disease,
             valvular heart disease, cardiomyopathy, aortic dissection, tachyarrhythmias,
             bradyarrhythmias, prior stroke or TIA; iii. prior hospitalization for heart failure;
             or iv. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves,
             ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock, left
             bundle branch block, second or third degree atrioventricular block).

          8. history of any disease requiring frequent intermittent or continuous systemic
             glucocorticoid treatment;

          9. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;

         10. history of any major illness with a life expectancy of &lt; 3 years;

         11. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity;

         12. excessive alcohol intake, acute or chronic;

         13. currently pregnant, or breastfeeding, or not using a reliable method of birth control
             for the duration of the trial in all females with childbearing potential;

         14. inability to take glargine, lixisenatide or metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia McInnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel Gerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Hall</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40667</phone_ext>
    <email>stephanie.hall@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Sigal, MD</last_name>
      <phone>403-955-8107</phone>
      <email>rsigal@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Azharuddin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joanne Liutkus</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Gelinas</last_name>
      <phone>519-624-8977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia McInnes, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>73794</phone_ext>
      <email>natalia.mcinnes@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ada Smith</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>22205</phone_ext>
      <email>smithad@mcmaster.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Hramiak, MD</last_name>
      <phone>519-646-6353</phone>
      <email>Irene.Hramiak@sjhc.london.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stewart Harris, MD</last_name>
      <phone>519-661-2111</phone>
      <email>Stewart.Harris@schulich.uwo.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Lochnan, MD</last_name>
      <email>hlochnan@toh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Lombardo</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36492</phone_ext>
      <email>angie.lombardo@muhc.mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>iGlarLixi</keyword>
  <keyword>Metformin</keyword>
  <keyword>Insulin</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

